Ovarian Cancer Coverage from Every Angle
Editor:
Joyce F. Liu, MD, MPH
Advertisement
Advertisement

News

ASCO 2025: A Noninvasive Diagnostic Tool for Ovarian Cancer
AACR 2025: Are OTTA-SPOT Scores an Accurate Prognostic Tool for Black Patients With Ovarian Cancer?
Significant Overall Survival Benefit Seen With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer
Clinical Impact of Variation in HRR Gene Mutations in High-Grade Serous Tubo-Ovarian Carcinoma
Repeated Laparoscopic Extensive Surgery for Rare Ovarian Cancer: Case Report
Translational Data From Early-Phase Trial of Novel Immunotherapy for Advanced Ovarian Cancer
FDA Grants Fast Track Designation to Novel Therapy for Platinum-Resistant Ovarian Cancer
Reproductive Factors and Risk of Epithelial Ovarian Cancer in Asian Women
Australian Clinical Trial to Assess Next-Generation Screening Test for Ovarian Cancer
Variations in Worldwide Patterns and Trends in Ovarian Cancer
Can Metabolic Imaging Discern Subtypes in High-Grade Serous Ovarian Cancer?
Molecular and Immune Disparities in High-Grade Serous Ovarian Cancer
RMAT Designation Granted by the FDA for Gemogenovatucel-T in Advanced Ovarian Cancer
FOLR1 as a Therapeutic Target in Low-Grade Serous Ovarian Carcinoma
Phase II PICCOLO Trial: Mirvetuximab Soravtansine-gynx in FRα-Positive, Platinum-Sensitive Ovarian Cancer
Use of Niraparib in Ovarian Cancer: Benefits of an Individualized Starting Dose
Genomic Instability: Linked to Survival Outcomes in BRCA1/2 Wild-Type Ovarian Cancer
Research Focuses on How to Boost Immunotherapy Response in Recurrent Ovarian Cancer
Real-World Analysis of FRα Testing Patterns in Epithelial Ovarian Cancer
Can Genomic Instability Predict Response to PARP Inhibitors in Ovarian Cancer?
Team at Wyss Institute Receives Award for New Treatment Paradigm in Ovarian Cancer
Can Targeting SMARCA4 Overcome Ovarian Cancer Immune Evasion?
SOLO3 Survival Update: Olaparib vs Nonplatinum Chemotherapy for Relapsed Ovarian Cancer
Epithelial Ovarian Cancer: Comparing Targeted Treatments With Standard-of-Care Chemotherapy
Understanding the Phenotypic Characteristics of Normal and Malignant Ovarian Cells
LANCE Trial to Compare Surgical Methods After Chemotherapy for Epithelial Ovarian Cancer
High-Grade Serous Ovarian Cancer: Molecular and Immune Diversity of mRNA Subtypes
Update on Overall Survival in Phase III Trial of Niraparib for Advanced Ovarian Cancer
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.